MIRA Pharmaceuticals gains approval for a Phase 1 trial of Ketamir-2 in Israel, aiming to complete by Q4 2025 before moving ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the approval and ...

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

Solving the shortage problem of Ketamine and unlocking its pharmaceutical potential Toronto, Ontario-- (Newsfile Corp. - March 3, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality ...

In South Florida, innovative ideas are being employed every day to deal with climate change threats. Start-up tech companies ...

The charges against Marcus Jordan, the son of NBA star Michael Jordan, have changed since his initial arrest on Feb. 4 in ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

Bryan Johnson, the American entrepreneur renowned for his anti-ageing endeavours, has disclosed the details of his latest ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).